alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<PAGE>
                                  EXHIBIT 23.1

               CONSENT OF FORTNER, BAYENS, LEVKULICH AND CO., P.C.

                       CONSENT OF INDEPENDENT ACCOUNTANTS'



To Board of Directors
Front Range Capital Corporation


         We consent to the use in the Form 10-QSB of Front Range Capital
Corporation for the quarterly period ended March 31, 2002 our report dated
May 2, 2002 relating to the consolidated balance sheet of Front Range Capital
Corporation and subsidiaries as of March 31, 2002 and the related consolidated
statements of income, comprehensive income and cash flows for the three-month
period then ended.







                                 /s/ Fortner, Bayens, Levkulich & Co., P.C.


Denver, Colorado
May 14, 2002
IIB 

118TH CONGRESS 

2D SESSION H. R. 7686 

IN THE SENATE OF THE UNITED STATES 

SEPTEMBER 10, 2024 

Received; read twice and referred to the Committee on Commerce, Science, 

and Transportation 

AN ACT 

To amend the Research and Development, Competition, and 

Innovation Act to clarify the definition of foreign country 

for purposes of malign foreign talent recruitment restriction, and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 


ssavage on LAPJG3WLY3PROD with BILLS
2 

HR 7686 RFS

1 SECTION 1. CLARIFICATION OF DEFINITION OF FOREIGN 

2 COUNTRY FOR PURPOSES OF MALIGN FOR3 EIGN TALENT RECRUITMENT RESTRICTION. 

4 Paragraph (4) of section 10638 of title VI of division 

5 B of the Research and Development, Competition, and In6 novation Act is amended— 

7 (1) by inserting ‘‘of concern’’ after ‘‘foreign 

8 country’’ each place such term appears; 

9 (2) by striking ‘‘means—’’ and all that follows 

10 through ‘‘any program, position, or activity’’ and in11 serting ‘‘means any program, position, or activity’’; 

12 (3) by striking subparagraph (B); 

13 (4) by redesignating clauses (i) through (ix) as 

14 subparagraphs (A) through (I), respectively, and 

15 moving such subparagraphs, as so redesignated, two 

16 ems to the left; 

17 (5) in the matter preceding subparagraph (A), 

18 as so redesignated, by striking ‘‘directly provided’’ 

19 and inserting ‘‘whether directly or indirectly pro20 vided’’; and 


ssavage on LAPJG3WLY3PROD with BILLS
3 

HR 7686 RFS

1 (6) in subparagraph (I), as so redesignated, by 

2 striking ‘‘; and’’ and inserting a period. 

Passed the House of Representatives September 9, 

2024. 

Attest: KEVIN F. MCCUMBER, 

Clerk. 


ssavage on LAPJG3WLY3PROD with BILLS
§ 74.2602 D&C Violet No. 2. ( a ) *Identity and specifications.* The color additive D&C Violet No. 2 shall conform in identity and specifications to the requirements of § 74.1602(a)(1) and (b).
( b ) *Uses and restrictions.* The color additive D&C Violet No. 2 may be safely used for coloring externally applied cosmetics in amounts consistent with good manufacturing practice.
( c ) *Labeling.* The label of the color additive shall conform to the requirements of § 70.25 of this chapter.
( d ) *Certification.* All batches of D&C Violet No. 2 shall be certified in accordance with regulations in part 80 of this chapter.
EPA-420-F-12-007

 January 2012

Independent Commercial Importers 

The following is a list of Independent Commercial Importers (ICIs) who currently hold a valid Certificate 

of Conformity from EPA. This certificate allows the ICI to import certain nonconforming vehicles into the 

U. S., THE MAKES OR MODELS THAT AN ICI CAN IMPORT ARE LIMITED. You should contact the 

ICI to determine if it is qualified to import your particular vehicle and if it currently has a valid Certificate 

of Conformity.

Auto Boutique Ltd. G & K Automotive J.K Technologies, LLC 

660 Baker St. 405-V Conversion, Inc. 3500 Sweet Air Street

Costa Mesa, CA 92626 2530 S. Birch Street Baltimore, MD 21211 

Rep: Makoto Harada Santa Ana, CA 92707 Rep: Jonathan Weisheit 

Phone: (714) 668-0235 Phone (714) 545-9503 Phone: (410) 366-6332 

Email: epa@autoboutique.us Fax: (714) 545-7667 Fax: (410) 366-7655 

 Email: george@gnkauto.com Email: convert2us@aol.com

Northern California Right Hand Drive Japan US Drive Right

Diagnostic Laboratories, Inc. 20437 Hawthorne Blvd P.O. Box 492 

2748 Jefferson Street Torrance, CA 90503 Spring Arbor, MI 49283 

Napa, CA 84558-4936 Rep: Takahiro Fujimori Rep: Bruce Hildenbrand 

Rep: Mike Spencer-Smith Phone: (310) 452-4299 Phone: (517) 206-4486 

Phone: (707) 258-1753 Email: info@righthanddrivejapan.com Email: bruce@usdriveright.com

Fax: (707) 258-1611 

Email: ncdl@ncdlinc.com

US SPECS, LLC Wallace Environmental 

121Northway Drive Testing Laboratories 

Havre de Grace, MD 21078 2140 Wirtcrest 

Rep: Carl Brinegar Houston, TX 77055 

Phone: (443) 502-2331 Rep: Les Weaver

Fax: (443) 502-2331 Phone: (713) 956-7705 

Email: USSPECS@aol.com Fax: (713) 956-0104 

 Email: sales@wallacelab.com

 EPA DOES NOT ENDORSE OR RECOMMEND ANY PARTICULAR ICI ON THIS LIST. Test 

documentation for an individual vehicle and other information concerning the quality of modifications will 

be carefully scrutinized to determine whether such vehicle meets all applicable EPA requirements under the 

imports regulations.
# C_2014184EN.01004602.xml

| 16.6.2014 | EN | Official Journal of the European Union | C 184/46 |
| --- | --- | --- | --- |

16.6.2014

EN

Official Journal of the European Union

C 184/46

---

Action brought on 14 April 2014 — ZZ v OHIM

(Case F-35/14)

2014/C 184/78

Language of the case: English

Parties

Parties

Applicant: ZZ (represented by: A. Pappas, lawyer)

Applicant:

Defendant: Office for Harmonization in the Internal Market (Trade Marks and Designs) (OHIM)

Defendant:

Subject-matter and description of the proceedings

Subject-matter and description of the proceedings

The Annulment of the decision of OHIM, drafted on the grounds of the decision of the president of the Office of 29 March 2012 concerning teleworking, not to authorise the applicant to telework in Barcelona, and thus, obliging her to return to Alicante.

Form of order sought

Form of order sought

| — | Annul the contested decision; |
| --- | --- |

—

Annul the contested decision;

| — | order the Defendant to bear the costs. |
| --- | --- |

—

order the Defendant to bear the costs.

---
Exhibit 23.1
                                                                 ------------

            Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the post effective amendment
No.1 registration statement on Form S-8 of 1st Independence Financial Group,
Inc. (Company) (333-113163) , the registration statement of the Company on
Form S-8 (333-118198) and the registration statement of the Company on
Form S-8 (333-136725) of our report dated April 11, 2008, appearing in the
annual report on Form 10-K of the Company for the year ended December 31, 2007.


/s/ BKD, LLP

Louisville, Kentucky
April 11, 2008
# L1011 Full Flight Simulator
Relocation and Installation

1 LIFT - 1504 - 006 ATTACHMENT 

# April 14, 2015

# L1011 Full Flight Simulator Relocation

2

LIFT - 1504 - 006 ATTACHMENT 

# Simulator Flight Compartment Simulator components, Accessories and Computers

# Simulator Arrival, Unload, Open and Inspect

3

LIFT - 1504 - 006 ATTACHMENT 

# Flight Compartment Required Two Large Forklifts to Remove from the Truck Opening and Inspecting in Preparation for Installation

# Facility Renovations

4

LIFT - 1504 - 006 ATTACHMENT 

# Three, 6 Ft Deep Isolation Pads, filled with Cement and Rebar, were required to mount the attachment pads and legs. Two Roof Air conditioners were installed and ducting for the computer room and the simulator flight deck. A special boring machine was used to drill holes for the base plate anchor bolts The computer room required a raised floor to pump cool air up and into the cabinets

# Flight Compartment Installation

5

LIFT - 1504 - 006 ATTACHMENT 

# The simulator is raised into position block by block until its high

enough to install the main actuator legs

# Installing the Motion Actuator Legs

6

LIFT - 1504 - 006 ATTACHMENT

# Completion and Operation of the Computer 

# Room

7 LIFT - 1504 - 006 ATTACHMENT

# Completion of the Simulator and Pump Room 

# Installation

8 LIFT - 1504 - 006 ATTACHMENT
11TH COURT OF APPEALS

EASTLAND, TEXAS

JUDGMENT

Hector Haro, * From the 350th District Court

of Taylor County,

Trial Court No. 15208-D.

Vs. No. 11-22-00187-CR * May 16, 2024

The State of Texas, * Memorandum Opinion by Bailey, C.J. 

(Panel consists of: Bailey, C.J.,

Trotter, J., and Williams, J.)

This court has inspected the record in this cause and concludes that there is no 

error in the judgment below. Therefore, in accordance with this court’s opinion, 

the judgment of the trial court is in all things affirmed.
§ 582.1073 Phosphoric acid. ( a ) *Product.* Phosphoric acid.
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.
# C_2014159EN.01001401.xml

| 26.5.2014 | EN | Official Journal of the European Union | C 159/14 |
| --- | --- | --- | --- |

26.5.2014

EN

Official Journal of the European Union

C 159/14

---

Request for a preliminary ruling from the Juzgado de Primera Instancia No 5 de Cartagena (Spain) lodged on 14 March 2014 — Aktiv Kapital Portfolio Investments v Ángel Luis Egea Torregrosa

(Case C-122/14)

2014/C 159/19

Language of the case: Spanish

Referring court

Referring court

Juzgado de Primera Instancia No 5 de Cartagena

Parties to the main proceedings

Parties to the main proceedings

Applicant: Aktiv Kapital Portfolio Investments

Applicant:

Defendant: Ángel Luis Egea Torregrosa

Defendant:

Question referred

Question referred

Must Directive 93/13 (1) be interpreted as precluding a provision of national law like the Spanish legislation that does not allow the court to review of its own motion in limine litis, in the subsequent enforcement procedure, the judicial enforceable instrument — an order made by the court bringing the order-for-payment proceedings to an end in the absence of any objections — in order to ascertain whether there are unfair terms in the contract that served as a basis for the issue of that decree whose enforcement is sought, because national law considers the matter to be res judicata — Articles 551 and 552 of the Ley de Enjuiciamiento Civil [Code of Civil Procedure] in conjunction with Article 816(2) thereof?

1

in limine litis

res judicata

---

(1)  Council Directive 93/13/EEC of 5 April 1993 on unfair terms in consumer contracts OJ 1993 L 95, p. 29.

1

---
#### § 4.1 What is the scope of this subpart?

This subpart applies to combination products. It establishes which current good manufacturing practice requirements apply to these products. This subpart clarifies the application of current good manufacturing practice regulations to combination products, and provides a regulatory framework for designing and implementing the current good manufacturing practice operating system at facilities that manufacture co-packaged or single-entity combination products.
---

EXHIBIT 13.B





CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002



In connection with Amendment No. 2 to the Annual Report of Petaquilla Minerals Ltd. (the Company) on Form 20-F for the transition period ended May 31, 2008 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Bassam Moubarak, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:



1.

The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and



2.

The information contained in the Report fairly presents, in all materials respects, the financial condition and results of operations of the Company.





|                              | 
|----------------------------- | 
|/s/ Bassam Moubarak           | 
|Bassam Moubarak              
|(principal financial officer)



Dated:  November 6, 2009





The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C § 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.





---
**Exhibit 31.2**

 

**CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER**

** **

**PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

 

I, Timothy P. O’Neil,certify that:

 

1.  I have reviewed this annual report on Form10-K of LOUD Technologies Inc.;

 

2.  Based on my knowledge, this report does notcontain any untrue statement of a material fact or omit to state a materialfact necessary to make the statements made, in light of the circumstances underwhich such statements were made, not misleading with respect to the periodcovered by this report;

 

3.  Based on my knowledge, the financialstatements, and other financial information included in this report, fairlypresent in all material respects the financial condition, results of operationsand cash flows of the registrant as of, and for, the periods presented in thisreport;

 

4.  The registrant’s other certifying officer andI are responsible for establishing and maintaining disclosure controls andprocedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for theregistrant and have:

 

(a)  Designed suchdisclosure controls and procedures, or caused such disclosure controls andprocedures to be designed under our supervision, to ensure that materialinformation relating to the registrant, including its consolidatedsubsidiaries, is made known to us by others within those entities, particularlyduring the period in which this report is being prepared;

 

(b)  Evaluated theeffectiveness of the registrant’s disclosure controls and procedures andpresented in this report our conclusions about the effectiveness of thedisclosure controls and procedures, as of the end of the period covered by thisreport based on such evaluation; and

 

(c)  Disclosed inthis report any change in the registrant’s internal control over financialreporting that occurred during the registrant’s most recent fiscal quarter thathas materially affected, or is reasonably likely to materially affect, theregistrant’s internal control over financial reporting; and

 

5.  The registrant’s other certifying officer andI have disclosed, based on our most recent evaluation of   internal control over financial reporting,to the registrant’s auditors and the audit committee of the registrant’s boardof directors:

 

(a)  All significantdeficiencies and material weaknesses in the design or operation of internalcontrol over financial reporting which are reasonably likely to adverselyaffect the registrant’s ability to record, process, summarize and reportfinancial information; and

 

(b)  Any fraud,whether or not material, that involves management or other employees who have asignificant role in the registrant’s internal control over financial reporting.

 

 
| Dated:    March 31, 2005 | By:      |    /s/  Timothy P. O’Neil          |   |
|------------------------------------|----------|--------------------------------------------------------|--------|
|                               |     |   Timothy  P. O’Neil                    |
| * *                           | * * | *  Chief Financial Officer, Vice President,* |
| * *                           | * * | *  Secretary and Treasurer*                  |

 

1

----
# C_2014421EN.01006001.xml

| 24.11.2014 | EN | Official Journal of the European Union | C 421/60 |
| --- | --- | --- | --- |

24.11.2014

EN

Official Journal of the European Union

C 421/60

---

Action brought on 25 June 2014 — ZZ v Commission

(Case F-57/14)

2014/C 421/86

Language of the case: French

Parties

Parties

Applicant: ZZ (represented by: L. Massaux, lawyer)

Applicant:

Defendant: European Commission

Defendant:

Subject-matter and description of the proceedings

Subject-matter and description of the proceedings

Annulment of the decision to impose a disciplinary penalty consisting of a reprimand on the applicant following a disciplinary enquiry and the award of damages.

Form of order sought

Form of order sought

| — | Annul the decision of the Appointing Authority dated 19 March 2014, notified on 20 March 2014 and, so far as is necessary, the decision dated 6 September 2013 adopted by the DG Human Resources and Security; |
| --- | --- |

—

Annul the decision of the Appointing Authority dated 19 March 2014, notified on 20 March 2014 and, so far as is necessary, the decision dated 6 September 2013 adopted by the DG Human Resources and Security;

| — | Order the Commission to pay the applicant the sum calculated ex aequo et bono of EUR 5  000; |
| --- | --- |

—

Order the Commission to pay the applicant the sum calculated ex aequo et bono of EUR 5  000;

ex aequo et bono

| — | Order the Commission to pay the Costs. |
| --- | --- |

—

Order the Commission to pay the Costs.

---
#### § 522.1660 Oxytetracycline injectable dosage forms.
COURT OF APPEALS

SECOND DISTRICT OF TEXAS

FORT WORTH

NO. 02-10-00309-CV

KENNETH P. GROSS AND

BETSY L. GROSS

APPELLANTS

V.

WB TEXAS RESORT 

COMMUNITIES, L.P.

APPELLEE

----------

FROM THE 141ST DISTRICT COURT OF TARRANT COUNTY

----------

MEMORANDUM OPINION1

----------

Twice we have abated this case on Appellants’ motions pending entry of a 

final judgment or order from which they may appeal. In our most recent 

abatement order, we stated that if a supplemental clerk’s record containing a final 

judgment was not filed by December 14, 2010, then we could dismiss this case 

for want of jurisdiction.

 

1See Tex. R. App. P. 47.4.
2

On December 14, 2010, Appellants notified us that they were unable to 

secure a final order or judgment from the trial court by that date and that 

therefore they had no choice but to allow the appeal to be dismissed without 

prejudice. Accordingly, this appeal is dismissed for want of jurisdiction. See Tex. 

R. App. P. 42.3(a), 43.2(f).

PER CURIAM

PANEL: GABRIEL, J.; LIVINGSTON, C.J.; and DAUPHINOT, J.

DELIVERED: January 27, 2011
Editorial Note on Part 312
Editorial Note: Nomenclature changes to part 312 appear at 69 FR 13717, Mar. 24, 2004.

§ 312.320 Treatment IND or treatment protocol. Under this section, FDA may permit an investigational drug to be used for widespread treatment use. ( a ) *Criteria.* The criteria in § 312.305(a) must be met, and FDA must determine that: ( 1 ) *Trial status.* ( i ) The drug is being investigated in a controlled clinical trial under an IND designed to support a marketing application for the expanded access use, or
( ii ) All clinical trials of the drug have been completed; and
( 2 ) *Marketing status.* The sponsor is actively pursuing marketing approval of the drug for the expanded access use with due diligence; and
( 3 ) *Evidence.* ( i ) When the expanded access use is for a serious disease or condition, there is sufficient clinical evidence of safety and effectiveness to support the expanded access use. Such evidence would ordinarily consist of data from phase 3 trials, but could consist of compelling data from completed phase 2 trials; or
( ii ) When the expanded access use is for an immediately life-threatening disease or condition, the available scientific evidence, taken as a whole, provides a reasonable basis to conclude that the investigational drug may be effective for the expanded access use and would not expose patients to an unreasonable and significant risk of illness or injury. This evidence would ordinarily consist of clinical data from phase 3 or phase 2 trials, but could be based on more preliminary clinical evidence.
( b ) *Submission.* The expanded access submission must include information adequate to satisfy FDA that the criteria in § 312.305(a) and paragraph (a) of this section have been met. The expanded access submission must meet the requirements of § 312.305(b).
( c ) *Safeguard.* The sponsor is responsible for monitoring the treatment protocol to ensure that licensed physicians comply with the protocol and the regulations applicable to investigators.
<PAGE>   1
                                    Exhibit 5

                            LEGAL OPINION AND CONSENT





May 19, 1999


Columbia Bancorp
P.O. Box 1050
The Dalles, Oregon  97058

               RE:    COLUMBIA BANCORP - FORM S-8 REGISTRATION STATEMENT

To Columbia Bancorp:

               I have served as counsel to Columbia Bancorp (the "Company") in
connection with the Registration Statement of the Company on Form S-8 (the
"Registration Statement") under the Securities Act of 1933, as amended, for the
registration of 318,597 shares of common stock, no par value, of the Company
(the "Shares"). The Shares are to be issued under and pursuant to the Company's
1999 Stock Incentive Plan (the "Plan").

               In connection with the Registration Statement, I advise you that,
in my opinion, when the Shares have been issued and sold pursuant to the
provisions of the Plan, and in accordance with the Registration Statement, the
Shares will be duly authorized, validly issued, fully paid and non-assessable.

               I hereby consent to the filing of this opinion letter as an
Exhibit to the Registration Statement.

                                                   Very truly yours,

                                                   /s/
                                                   -----------------------------
                                                   Bennett H. Goldstein
§ 640.94 Labeling. In addition to the labeling requirements of §§ 610.60, 610.61, and 610.62 of this chapter, the container and package labels shall contain the following information: ( a ) The osmotic equivalent in terms of plasma, and the sodium concentration in terms of a value or a range in milliequivalents per liter.
( b ) The cautionary statement placed in a prominent position on the label, “Do Not Use if Turbid. Do Not Begin Administration More than 4 Hours After the Container Has Been Entered.”
[42 FR 27583, May 31, 1977, as amended at 49 FR 2244, Jan. 19, 1984; 64 FR 26286, May 14, 1999]